These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

438 related articles for article (PubMed ID: 9865906)

  • 41. PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner.
    Bos M; Mendelsohn J; Kim YM; Albanell J; Fry DW; Baselga J
    Clin Cancer Res; 1997 Nov; 3(11):2099-106. PubMed ID: 9815602
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Different classes of EGFR inhibitors may have different potential to improve local tumour control after fractionated irradiation: a study on C225 in FaDu hSCC.
    Krause M; Schütze C; Petersen C; Pimentel N; Hessel F; Harstrick A; Baumann M
    Radiother Oncol; 2005 Feb; 74(2):109-15. PubMed ID: 15734198
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Antitumor effect of FP3 in combination with cetuximab on patient-derived tumor tissue xenograft models of primary colon carcinoma and related lymphatic and hepatic metastases.
    Dong X; Jin K; Hu X; Du F; Lan H; Han N; Ma Z; Xie B; Cui B; Teng L; Cao F
    Int J Mol Med; 2012 Jul; 30(1):126-32. PubMed ID: 22505231
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice.
    Pollack VA; Savage DM; Baker DA; Tsaparikos KE; Sloan DE; Moyer JD; Barbacci EG; Pustilnik LR; Smolarek TA; Davis JA; Vaidya MP; Arnold LD; Doty JL; Iwata KK; Morin MJ
    J Pharmacol Exp Ther; 1999 Nov; 291(2):739-48. PubMed ID: 10525095
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR.
    Luwor RB; Johns TG; Murone C; Huang HJ; Cavenee WK; Ritter G; Old LJ; Burgess AW; Scott AM
    Cancer Res; 2001 Jul; 61(14):5355-61. PubMed ID: 11454674
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Inhibition of metastatic renal cell carcinomas expressing somatostatin receptors by a targeted cytotoxic analogue of somatostatin AN-238.
    Plonowski A; Schally AV; Nagy A; Kiaris H; Hebert F; Halmos G
    Cancer Res; 2000 Jun; 60(11):2996-3001. PubMed ID: 10850448
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Enhanced response to C225 of A431 tumor xenografts growing in irradiated tumor bed.
    Riesterer O; Mason KA; Raju U; Yang Q; Wang L; Hittelman WN; Ang KK; Milas L
    Radiother Oncol; 2009 Sep; 92(3):383-7. PubMed ID: 19695723
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Requirement for the von Hippel-Lindau tumor suppressor gene for functional epidermal growth factor receptor blockade by monoclonal antibody C225 in renal cell carcinoma.
    Perera AD; Kleymenova EV; Walker CL
    Clin Cancer Res; 2000 Apr; 6(4):1518-23. PubMed ID: 10778984
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Blockade of growth factor receptors in ductal carcinoma in situ inhibits epithelial proliferation.
    Chan KC; Knox WF; Gandhi A; Slamon DJ; Potten CS; Bundred NJ
    Br J Surg; 2001 Mar; 88(3):412-8. PubMed ID: 11260109
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Modulation of tumor growth and tumor induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 in renal cell carcinoma.
    Asakuma J; Sumitomo M; Asano T; Asano T; Hayakawa M
    J Urol; 2004 Feb; 171(2 Pt 1):897-902. PubMed ID: 14713849
    [TBL] [Abstract][Full Text] [Related]  

  • 51. C225 antiepidermal growth factor receptor antibody enhances the efficacy of docetaxel chemoradiotherapy.
    Nakata E; Hunter N; Mason K; Fan Z; Ang KK; Milas L
    Int J Radiat Oncol Biol Phys; 2004 Jul; 59(4):1163-73. PubMed ID: 15234052
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Dose-dependent increases in circulating TGF-alpha and other EGFR ligands act as pharmacodynamic markers for optimal biological dosing of cetuximab and are tumor independent.
    Mutsaers AJ; Francia G; Man S; Lee CR; Ebos JM; Wu Y; Witte L; Berry S; Moore M; Kerbel RS
    Clin Cancer Res; 2009 Apr; 15(7):2397-405. PubMed ID: 19276250
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin.
    Baselga J; Pfister D; Cooper MR; Cohen R; Burtness B; Bos M; D'Andrea G; Seidman A; Norton L; Gunnett K; Falcey J; Anderson V; Waksal H; Mendelsohn J
    J Clin Oncol; 2000 Feb; 18(4):904-14. PubMed ID: 10673534
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Conservation of receptor antagonist anti-tumor activity by epidermal growth factor receptor antibody expressed in transgenic corn seed.
    Ludwig DL; Witte L; Hicklin DJ; Prewett M; Bassi R; Burtrum D; Pereira DS; Jimenez X; Fox F; Saxena B; Zhou Q; Ma Y; Kang X; Patel D; Barry M; Kussie P; Zhu Z; Russell DA; Petersen WL; Jury TP; Gaitan-Gaitan F; Moran DL; Delannay X; Storrs BS; Tou J; Zupec ME; Gustafson KS; McIntyre J; Tarnowski SJ; Bohlen P
    Hum Antibodies; 2004; 13(3):81-90. PubMed ID: 15598988
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Epidermal growth factor receptor and tumor response to radiation: in vivo preclinical studies.
    Milas L; Fan Z; Andratschke NH; Ang KK
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):966-71. PubMed ID: 14967457
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Treatment of pancreatic cancer xenografts with Erbitux (IMC-C225) anti-EGFR antibody, gemcitabine, and radiation.
    Buchsbaum DJ; Bonner JA; Grizzle WE; Stackhouse MA; Carpenter M; Hicklin DJ; Bohlen P; Raisch KP
    Int J Radiat Oncol Biol Phys; 2002 Nov; 54(4):1180-93. PubMed ID: 12419447
    [TBL] [Abstract][Full Text] [Related]  

  • 57. IGF-I and IGFBP-3 augment transforming growth factor-beta actions in human renal carcinoma cells.
    Rosendahl AH; Forsberg G
    Kidney Int; 2006 Nov; 70(9):1584-90. PubMed ID: 16969385
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Activity of anti-epidermal growth factor receptor monoclonal antibody C225 against glioblastoma multiforme.
    Eller JL; Longo SL; Hicklin DJ; Canute GW
    Neurosurgery; 2002 Oct; 51(4):1005-13; discussion 1013-4. PubMed ID: 12234411
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Decreased repopulation as well as increased reoxygenation contribute to the improvement in local control after targeting of the EGFR by C225 during fractionated irradiation.
    Krause M; Ostermann G; Petersen C; Yaromina A; Hessel F; Harstrick A; van der Kogel AJ; Thames HD; Baumann M
    Radiother Oncol; 2005 Aug; 76(2):162-7. PubMed ID: 16024114
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Oral naftopidil suppresses human renal-cell carcinoma by inducing G(1) cell-cycle arrest in tumor and vascular endothelial cells.
    Iwamoto Y; Ishii K; Sasaki T; Kato M; Kanda H; Yamada Y; Arima K; Shiraishi T; Sugimura Y
    Cancer Prev Res (Phila); 2013 Sep; 6(9):1000-6. PubMed ID: 23901046
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.